Witjes - Figure 57
GemRIS
FIG. 57: An intravesical drug delivery system is in clinical development for the controlled release of a drug, in this case gemcitabine, over a 7-day period. A Phase Ib study with TAR-200 (GemRIS™) has been completed in muscle-invasive bladder cancer in the United States[47] and another Phase 1b study in NMI bladder cancer is ongoing in Europe.[48]
References
Taris Biomedical. Safety and tolerability of GemRIS™ 225 mg in subjects with muscle-invasive bladder cancer. ClinicalTrials.gov Identifier: NCT02722538. May 8, 2017 https://clinicaltrials.gov/ct2/show/NCT02720367 Accessed August 6, 2017
Taris Biomedical. Safety and tolerability of GemRIS™ 225 mg in subjects with muscle-invasive bladder cancer. ClinicalTrials.gov Identifier: NCT02722538. May 8, 2017 https://clinicaltrials.gov/ct2/show/NCT02722538 Accessed August 6, 2017